Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France].
Broussais F, Bay JO, Boissel N, Baruchel A, Arnulf B, Morschhauser F, Robin M, Guepin GR, Moreau P, Gandemer V, Manier S, Leguay T, Nguyen Quoc S, Schwartzmann A, Houot R, Le Gouill S. Broussais F, et al. Among authors: morschhauser f. Bull Cancer. 2021 Oct;108(10S):S143-S154. doi: 10.1016/j.bulcan.2021.07.002. Bull Cancer. 2021. PMID: 34920797 French.
[Indications of G-CSF administration in hematologic disorders].
Lionne-Huyghe P, Kuhnowski F, Coiteux V, Bauters F, Morschhauser F. Lionne-Huyghe P, et al. Among authors: morschhauser f. Bull Cancer. 2006 May;93(5):453-62. Bull Cancer. 2006. PMID: 16777623 Free article. Review. French.
Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
Bodet-Milin C, Kraeber-Bodéré F, Dupas B, Morschhauser F, Gastinne T, Le Gouill S, Campion L, Harousseau JL, Wegener WA, Goldenberg DM, Huglo D. Bodet-Milin C, et al. Among authors: morschhauser f. Haematologica. 2008 Mar;93(3):390-7. doi: 10.3324/haematol.10591. Epub 2008 Feb 11. Haematologica. 2008. PMID: 18268287 Free article. Clinical Trial.
High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
Morschhauser F, Kraeber-Bodéré F, Wegener WA, Harousseau JL, Petillon MO, Huglo D, Trümper LH, Meller J, Pfreundschuh M, Kirsch CM, Naumann R, Kropp J, Horne H, Teoh N, Le Gouill S, Bodet-Milin C, Chatal JF, Goldenberg DM. Morschhauser F, et al. J Clin Oncol. 2010 Aug 10;28(23):3709-16. doi: 10.1200/JCO.2009.27.7863. Epub 2010 Jul 12. J Clin Oncol. 2010. PMID: 20625137 Clinical Trial.
Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.
Bachy E, Houot R, Morschhauser F, Sonet A, Brice P, Belhadj K, Cartron G, Audhuy B, Fermé C, Feugier P, Sebban C, Delwail V, Maisonneuve H, Le Gouill S, Lefort S, Brousse N, Foussard C, Salles G; Groupe d'Etude des Lymphomes de l'Adulte (GELA). Bachy E, et al. Among authors: morschhauser f. Haematologica. 2013 Jul;98(7):1107-14. doi: 10.3324/haematol.2012.082412. Epub 2013 May 3. Haematologica. 2013. PMID: 23645690 Free PMC article. Clinical Trial.
[Brentuximab vedotin: new treatment for CD30+ lymphomas].
Terriou L, Bonnet S, Debarri H, Demarquette H, Morschhauser F. Terriou L, et al. Among authors: morschhauser f. Bull Cancer. 2013 Jul-Aug;100(7-8):775-9. doi: 10.1684/bdc.2013.1778. Bull Cancer. 2013. PMID: 23831822 Review. French.
The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype.
Lefèvre G, Copin MC, Staumont-Sallé D, Avenel-Audran M, Aubert H, Taieb A, Salles G, Maisonneuve H, Ghomari K, Ackerman F, Legrand F, Baruchel A, Launay D, Terriou L, Leclech C, Khouatra C, Morati-Hafsaoui C, Labalette M, Borie R, Cotton F, Gouellec NL, Morschhauser F, Trauet J, Roche-Lestienne C, Capron M, Hatron PY, Prin L, Kahn JE; French Eosinophil Network. Lefèvre G, et al. Among authors: morschhauser f. Medicine (Baltimore). 2014 Oct;93(17):255-266. doi: 10.1097/MD.0000000000000088. Medicine (Baltimore). 2014. PMID: 25398061 Free PMC article.
Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA.
Houot R, Soussain C, Tilly H, Haioun C, Thieblemont C, Casasnovas O, Bouabdallah K, Morschhauser F, Le Gouill S, Salles GA, Hoang-Xuan K, Choquet S, Marchand T, Laurent C, Pangault C, Lamy T. Houot R, et al. Among authors: morschhauser f. Ann Oncol. 2016 Jul;27(7):1349-50. doi: 10.1093/annonc/mdw138. Epub 2016 Mar 21. Ann Oncol. 2016. PMID: 27002105 Free article. Clinical Trial. No abstract available.
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
Coiffier B, Thieblemont C, de Guibert S, Dupuis J, Ribrag V, Bouabdallah R, Morschhauser F, Navarro R, Le Gouill S, Haioun C, Houot R, Casasnovas O, Holte H, Lamy T, Broussais F, Payrard S, Hatteville L, Tilly H. Coiffier B, et al. Among authors: morschhauser f. Br J Haematol. 2016 Jun;173(5):722-30. doi: 10.1111/bjh.13992. Epub 2016 Mar 24. Br J Haematol. 2016. PMID: 27010483 Free article. Clinical Trial.
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial.
Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker LM, Recher C, Ghesquieres H, Morschhauser F, Girault S, Le Gouill S, Ojeda-Uribe M, Mariette C, Cornillon J, Cartron G, Verge V, Chassagne-Clément C, Dombret H, Coiffier B, Lamy T, Tilly H, Salles G. Ribrag V, et al. Among authors: morschhauser f. Lancet. 2016 Jun 11;387(10036):2402-11. doi: 10.1016/S0140-6736(15)01317-3. Epub 2016 Apr 11. Lancet. 2016. PMID: 27080498 Clinical Trial.
305 results